Liquid Biopsy CDx Test for Advanced Non-small Cell Lung Canc

The US Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). Click to read more...

Related Keywords

Alan Sandler , Kenna Anderes , Sam Raha , Genomics Group , Drug Administration , Agilent Resolution , Vice President , Translational Medicine , Chief Medical , Ctdx , Patients , Approved , Agilent , Dvanced , Dancer , Nsclc , Profiling , Enomic , Iagnostics ,